In this health-focused program, Dr. Andrew Armstrong from Duke University highlights essential recent advances men need to understand to overcome prostate cancer.
The discussion includes insights on prostate cancer diagnosis, such as the significance of Stage IV disease and a high Gleason score of 9, as seen in former President Joe Biden’s case.
Prostate cancer impacts approximately one in eight men in their lifetime. Screening primarily involves measuring prostate specific antigen (PSA) levels, although PSA is not exclusively linked to cancer, so doctors watch trends rather than fixed thresholds.
Men with family history or higher risk should consider earlier and more frequent screening, generally starting between ages 40 to 45, especially for those with risk factors such as Black ancestry or inheritable gene mutations. Otherwise, men aged 50 to 69 are commonly advised to undergo screening every 2 to 4 years.
If PSA levels rise or are elevated, further evaluation including magnetic resonance imaging (MRI) and guided biopsies can detect tumors and help assign a Gleason score determining cancer aggressiveness.
Advanced molecular scans like PSMA PET detect cancer spread beyond the prostate, critical in Stage IV diagnosis, which involves metastasis often to bones. Genetic testing for mutations such as BRCA2 informs risk and potential treatment.
Prevention efforts emphasize lifestyle factors: avoiding environmental toxins, especially plastics, consuming cruciferous vegetables like broccoli and cabbage, and maintaining regular, vigorous exercise. Exercise also helps counteract side effects from therapies that reduce testosterone, a hormone fueling many prostate cancers.
Treatment methods include hormone therapies to block testosterone production and action, such as androgen deprivation therapy (ADT) and newer androgen receptor inhibitors, alongside surgery, radiation, and innovative immune therapies like Pluvicto that target cancer cells specifically.
These advances extend life, improve quality of life, and offer hope even in metastatic cases. Dr. Armstrong encourages seeking second opinions and multidisciplinary care to optimize outcomes.
Overall, early detection remains crucial because many men with prostate cancer do not die of the disease itself but from other causes. Men should have informed discussions with their healthcare providers about personalized screening plans and treatment options to manage their health proactively.
Read more:
